Ramelteon marketed as Rozerem by Takeda Pharmaceuticals North America is the first in a new class of sleep agents that selectively binds to the MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) instead of binding to GABA A receptors such as with drugs like zolpidem eszopiclone and zaleplon. Ramelteon is approved by the U.S.
This page contains content from the copyrighted Wikipedia article "Ramelteon"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
